Background-On the basis of studies with limited statistical power, lipoprotein(a) [Lp(a)] is not considered a risk factor for cardiovascular disease (CVD) in blacks. We evaluated associations between Lp(a) and incident CVD events in blacks and whites in the Atherosclerosis Risk in Communities (ARIC) study. Methods and Results-Plasma Lp(a) was measured in blacks (nϭ3467) and whites (nϭ9851). Hazards ratios (HRs) for incident CVD events (coronary heart disease and ischemic strokes) were calculated. Lp(a) levels were higher with wider interindividual variation in blacks (median [interquartile range], 12.8 [7.1-21.7] mg/dL) than whites (4.3 [1.7-9.5] mg/dL; PϽ0.0001). At 20 years of follow-up, 676 CVD events occurred in blacks, and 1821 events occurred in whites. Adjusted HRs (95% confidence interval) per race-specific 1-SD-greater log-transformed Lp(a) were 1.13 (1.04 -1.23) for incident CVD, 1.11 (1.00 -1.22) for incident coronary heart disease, and 1.21 (1.06 -1.39) for ischemic strokes in blacks. For whites, the respective HRs (95% confidence intervals) were 1. [Lp(a)] is considered a risk factor for cardiovascular disease (CVD) in whites on the basis of its association with measures of atherosclerosis and incident coronary heart disease (CHD) events, 1-9 the association between Lp(a) level and CVD risk in blacks is not clear, 5,10 -14 despite blacks' having 2 to 4 times higher Lp(a) levels than whites. 12, 15, 16 In the meta-analysis performed by the Emerging Risk Factors Collaboration, 1 although Lp(a) was associated with CHD in whites, these associations were not significant in blacks (261 CHD events occurred in blacks compared with 7540 in whites). The Adult Treatment Panel III guidelines also note that "although Lp(a) levels are higher in African Americans than in Caucasians, an increased risk for CHD associated with higher Lp(a) levels in African Americans has not been documented." 17 Similarly, a European Atherosclerosis Society consensus statement noted that the evidence to date does not answer whether Lp(a) is responsible for the high incidence rate of stroke in blacks and emphasized the need for further effort to assess atherothrombotic risk due to Lp(a) Ascertainment of additional CHD events and ischemic strokes in the ARIC cohort since these initial publications provides the opportunity to study the associations between Lp(a) and cardiovascular events in the black participants with greater statistical power.
A lthough elevated lipoprotein(a) [Lp(a)] is considered a risk factor for cardiovascular disease (CVD) in whites on the basis of its association with measures of atherosclerosis and incident coronary heart disease (CHD) events, [1] [2] [3] [4] [5] [6] [7] [8] [9] the association between Lp(a) level and CVD risk in blacks is not clear, 5,10 -14 despite blacks' having 2 to 4 times higher Lp(a) levels than whites. 12, 15, 16 In the meta-analysis performed by the Emerging Risk Factors Collaboration, 1 although Lp(a) was associated with CHD in whites, these associations were not significant in blacks (261 CHD events occurred in blacks compared with 7540 in whites). The Adult Treatment Panel III guidelines also note that "although Lp(a) levels are higher in African Americans than in Caucasians, an increased risk for CHD associated with higher Lp(a) levels in African Americans has not been documented." 17 Similarly, a European Atherosclerosis Society consensus statement noted that the evidence to date does not answer whether Lp(a) is responsible for the high incidence rate of stroke in blacks and emphasized the need for further effort to assess atherothrombotic risk due to Lp(a) in different ethnicities. 18 
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Few prospective studies have evaluated the associations between Lp(a) levels and incident CVD events in blacks because blacks have not been well represented in established longitudinal cohort studies. The Atherosclerosis Risk in Communities (ARIC) study, given its biracial population, provides an opportunity to study associations between elevated Lp(a) levels and incident CVD events in blacks. In an earlier publication from the ARIC study evaluating CHD outcomes in up to 10 years of follow-up, although the relative risks per 1-SD higher Lp(a) level for incident CHD were statistically significant for white men and women, they were not significant for black men or women. 19 One reason postulated to explain this result was that the number of CHD events was low in blacks (of a total of 725 CHD events, 90 occurred in black men, and 68 occurred in black women). Another study in the ARIC cohort showed that although Lp(a) levels were associated positively with ischemic strokes in black women (relative risk, 1.84; 95% confidence interval [CI], 1.05-3.07), the results were not statistically significant in black men (relative risk, 1.72; 95% CI, 0.86 -3.48). 20 Ascertainment of additional CHD events and ischemic strokes in the ARIC cohort since these initial publications provides the opportunity to study the associations between Lp(a) and cardiovascular events in the black participants with greater statistical power.
Our aim was thus to study the associations between Lp(a) and incident CVD events, incident CHD events, and incident ischemic strokes in black and white ARIC participants at up to 20 years of follow-up from the baseline examination.
Methods

Study Population
The ARIC study is a prospective epidemiological study of CVD incidence primarily among black and white adults (nϭ15 792).
ARIC participants were selected to be representative of adults aged 45 to 64 years living in 4 communities in the United States between 1987 and 1989. A complete description of the study design, objectives, and sampling strategy has been described previously. 21 For the present analyses, we excluded participants with prevalent CHD (nϭ1110) or prevalent stroke (nϭ336) at the baseline ARIC visit (1987) (1988) (1989) , those in whom the self-reported race was not black or white or was not known (nϭ43), blacks in Minneapolis and Washington County, Maryland (nϭ48), and participants using lipid-lowering medications (nϭ353) or missing data on lipid-lowering medication use (nϭ105) at the baseline ARIC visit. Of the remaining 13 797 participants, 13 318 (3467 blacks and 9851 whites) had Lp(a) measurements, and these participants formed the study population for the present analyses. Research protocols were approved by the institutional review board at each participating institution, and all participants provided written informed consent.
Information about covariates of interest was obtained by history and examinations at the baseline visit. 21 Sitting blood pressure and venipuncture were performed with the use of published techniques. Smoking status and the use of antihypertensive and lipid-lowering medications were assessed by a standardized questionnaire. Hypertension was defined as systolic blood pressure Ն140 mm Hg, diastolic blood pressure Ն90 mm Hg, prior physician diagnosis of hypertension, or use of antihypertensive medications. Diabetes mellitus was defined as either a self-reported history of diabetes mellitus, physician-diagnosed diabetes mellitus, the use of prescribed hypoglycemic medications, nonfasting glucose Ն200 mg/dL, or blood glucose Ն126 mg/dL after the subject was fasting at least 8 hours.
Baseline Laboratory Measurements
Lipid assays were performed on 12-hour fasting plasma samples collected on ice with ethylenediaminetetraacetic acid used as the anticoagulant. Cholesterol (total and high-density lipoprotein cholesterol [HDL-C]) and triglycerides were measured enzymatically. Low-density lipoprotein cholesterol (LDL-C) levels were calculated with the Friedewald equation. 22 The assay characteristics for base- 24 with essentially no within-person variability (indicative of a largely genetic predisposition), in a small sample of individuals. Most of the measurements were performed within 6 weeks of the receipt of the samples.
Ascertainment of Incident CHD Events and Incident Ischemic Strokes
Our outcome of interest was incident CVD events, which included incident CHD events and incident ischemic strokes. The ascertainment procedure for incident CHD events has been described previously. 25 Briefly, incident CHD events included CHD death, myocardial infarction, silent infarction identified by ECG, coronary artery bypass surgery, and coronary angioplasty occurring on or before December 31, 2007. Death and hospitalization events were ascertained by annual follow-up calls and community hospital surveillance. CHD death was defined as death lacking a probable non-CHD cause and with a recent myocardial infarction, chest pain within 72 hours of death, or history of CHD.
For the ascertainment of incident ischemic strokes, we surveyed discharge lists from local hospitals and death certificates from state vital statistics offices. An abstractor recorded signs and symptoms and photocopied neuroimaging (computed tomography or magnetic resonance imaging) and other diagnostic reports if the discharge diagnoses included a cerebrovascular disease code (International Classification of Diseases, Ninth Revision, codes 430 -438), if a cerebrovascular condition or procedure was mentioned in the discharge summary, or if a cerebrovascular finding was noted on a computed tomography or magnetic resonance imaging report. Each eligible case was classified according to criteria adapted from the National Survey of Stroke. 26, 27 Qualifying strokes were further classified as definite or probable ischemic (cardioembolic or thrombotic) or hemorrhagic stroke on the basis of neuroimaging studies and autopsy, when available. A stroke was classified as ischemic if a brain Values are expressed as means except percentages and triglycerides (median). LDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. *Women only.
computed tomography or magnetic resonance image revealed acute infarction or showed no evidence of hemorrhage.
Statistical Analyses
Median Lp(a) levels were compared between blacks and whites (and between men and women) with the use of an ANOVA test. Using traditional risk factors from baseline data, we defined risk factors for incident CVD events using a Cox proportional hazards model. The proportional hazards assumption was confirmed. Multivariable proportional hazards analysis was performed to assess whether Lp(a) contributed independently to the adjusted models. Adjustment model 1 included age and gender as covariates. Adjustment model 2 included age, gender, current smoking, systolic blood pressure, use of antihypertensive medications, and diabetes mellitus. Adjustment model 3 (fully adjusted model) included age, gender, current smoking, systolic blood pressure, use of antihypertensive medications, diabetes mellitus, LDL-C, HDL-C, and triglycerides as covariates. First, we performed quintile analyses (separately for blacks and whites) using the lowest Lp(a) quintile as the referent. Hazard ratios (HRs) were then calculated for the second, third, fourth, and highest quintiles, with adjustment for the covariates. To account for the skewed Lp(a) distribution, HRs associated with a 1-SD increase in log-transformed Lp(a) levels were calculated, followed by adjustment for the covariates of interest. Finally, we calculated HRs using Lp(a) cutoffs of Յ10 mg/dL, Ͼ10 to Յ20 mg/dL, Ͼ20 to Յ30 mg/dL, and Ͼ30 mg/dL, using Lp(a) levels Յ10 mg/dL as the referent group and adjusting for the covariates described above. Analyses were performed with the use of R version 2.11.1. All analyses were performed with 2-tailed tests for significance. A P value Ͻ0.05 was considered statistically significant.
Results
The final analyses included 13 
Baseline Characteristics
Baseline characteristics of participants across Lp(a) quintiles are described in Tables 1 and 2 . For blacks, Lp(a) levels in the highest quintile ranged from Ͼ24 to 81.7 mg/dL (median for the highest quintileϭ32.1 mg/dL), whereas Lp(a) levels in the highest quintile for whites ranged from 13.5 to 80.3 mg/dL (median for the highest quintileϭ20.4 mg/dL). Among both ethnic groups, higher Lp(a) quintiles included a higher proportion of women and lower prevalence of estrogen or progesterone use (in women). With increasing Lp(a) levels, LDL-C and HDL-C levels tended to be higher, whereas triglyceride levels tended to be lower in both groups. Black ARIC study participants in higher Lp(a) quintiles also had a lower prevalence of smoking. Body mass index was not associated with Lp(a) levels. Although participants on lipidlowering medications (nϭ335) at baseline were excluded from these analyses, the proportions of participants across Lp(a) quintiles who were on any lipid-lowering medications at ARIC study visit 4 (1996 -1998) were 5.5%, 5.6%, 8.5%, 6.3%, and 10.7% for blacks and 13.9%, 10.9%, 11.3%, 12.6%, and 18.4% for whites. The proportions of participants across Lp(a) quintiles who were on statins at ARIC study visit 4 were 4.8%, 4.9%, 7.3%, 5.7%, and 2.9% for blacks and 10.6%, 7.9%, 8.8%, 10.0%, and 15.8% for whites.
Lp(a) Levels and Incident Cardiovascular Events
At Ϸ20 years of follow-up, there were 676 incident CVD events in blacks (481 CHD events and 283 ischemic strokes) and 1821 incident CVD events in whites (1564 CHD events and 380 ischemic strokes). Tables 3 and 4 describe the results of race-specific quintile analyses comparing HRs in the second, third, fourth, and highest quintiles of Lp(a) with those in the lowest quintile. For blacks, the associations were graded (P for trendϭ0.0004, 0.009, and 0.0004 for incident CVD, CHD, and ischemic strokes, respectively) but were statistically significant only for the highest Lp(a) quintile (Ͼ24 mg/dL) for incident CVD events and ischemic strokes. Although participants in the highest quintile had increased risk for CHD compared with those in the lowest quintile, this HR was not statistically significant (HR, 1.27; 95% CI, 0.94 -1.71). For whites, the associations were graded for incident CVD (P for trendϭ0.001) and CHD (P for trendϭ0.002) but not for ischemic strokes (P for trendϭ0.25). The HRs for incident CVD and CHD were statistically significant only for the highest quintile of Lp(a) (Ͼ13.5 mg/dL). The highest quintile in whites was roughly equivalent to the 50th percentile in blacks.
We also evaluated HRs for incident CVD events, CHD events, and ischemic strokes per race-specific 1-SD increase in log-transformed Lp(a) levels (Table 5) . For blacks, each 1-SD increase in Lp(a) level in model 3 was associated with a 13% increase in risk for incident CVD events, an 11% increase in risk for CHD events (borderline significant), and a 21% increase in risk for ischemic strokes. Thus, the relationships were numerically stronger for ischemic strokes than for CHD events. For white participants, each 1-SD increase in Lp(a) was associated with a 9% increase in risk for incident CVD and a 10% increase in risk for CHD events; the 7% increase in risk for ischemic strokes was not statistically significant. It is important to note, however, that the strength of this association was at least as strong in blacks as in whites.
Because it could be argued that the significant association between Lp(a) and incident CVD events seen in blacks could be a result of differences in SDs of Lp(a) levels in blacks and whites, we also calculated HRs in blacks and whites using cutoffs with 10-mg/dL increments in Lp(a) levels ( Table 6 ). The HRs based on absolute Lp(a) cutoffs were at least as strong in blacks as in whites for CVD and CHD and were numerically higher for ischemic strokes at Lp(a) levels Ͼ30 mg/dL in blacks compared with whites.
Stratified analyses on male and female participants (Tables 7 through 10) showed that Lp(a) levels were associated with increased risk for CVD, CHD, and ischemic strokes in both male and female subjects, with a larger range of relevant Lp(a) concentrations in female compared with male subjects.
We also performed separate analyses for black women, black men, white women, and white men using Lp(a) quintiles, SD of log-transformed Lp(a) levels, and absolute Lp(a) cutoffs (Tables I through III in the online-only Data Supplement). Although these analyses were limited given the small number of events in some subgroups, Lp(a) levels were broadly associated with CVD risk in both black and white men and women. However, the associations between Lp(a) and risk of ischemic strokes were more robust for blacks than for whites (especially white men). Because one could argue that the Lp(a) assay used in ARIC could be sensitive to apo(a) isoform size, we performed additional analyses using a newer Lp(a) assay that is insensitive to apo(a) isoform size when calibrated with the International Federation of Clinical Chemistry proposed reference material in molar units. 28 Using 100 ARIC visit-1 samples [from the entire Lp(a) distribution based on the original assay with equal representation from both genders and ethnic groups], we compared the results with the original Lp(a) assay with the results of the newer isoform size-insensitive Lp(a) assay. Despite Ϸ23 years of storage at Ϫ70°C, our Deming regression analysis ( Figure I in the online-only Data Supplement) showed a good correlation (rϭ0.88) between the 2 assays. Similarly, Bland-Altman plots (online-only Data Supplement Figure I ) did not show evidence of a systematic bias at high or low Lp(a) levels. On the basis of these analyses, the clinically relevant cutoff of 30 mg/dL by the original ARIC visit-1 Lp(a) assay is roughly equivalent to 39 mg/dL by the newer isoform size-insensitive Lp(a) assay.
Discussion
In this large population-based study of blacks and whites followed for up to 20 years, Lp(a) levels were positively associated with risk for incident CVD events in both races. The strength of association for incident CVD events was equivalent for blacks and whites. The association between ischemic strokes and Lp(a) levels was more robust in blacks. Although the associations tended to be graded, they were statistically significant only for the highest quintile of Lp(a) levels. The gradient for increase in risk was comparable between both groups, with a larger range of Lp(a) levels in blacks. Consistent with prior data, median Lp(a) levels were almost 3 times higher in blacks than in whites. 12, 15, 16 Elevated Lp(a) levels have been associated consistently with increased CHD risk in whites but not in blacks. 5, 13, 14 Similarly, mendelian randomization studies in whites also support a causal role of Lp(a) in atherosclerosis. 2 Although the exact reasons why elevated Lp(a) levels have not been consistently associated with increased CHD risk in blacks are not known, some have argued that apo(a) size is an important contributor. 29, 30 Small apo(a) isoforms are likely more atherogenic than large apo(a) isoforms, 29 which could partly explain why blacks may not have increased CHD risk despite elevated Lp(a) levels, because blacks have lower prevalence of small apo(a) isoforms compared with whites. 31 Paultre et al 30 showed that elevated levels of Lp(a) combined with small apo(a) isoforms were associated with the angiographic extent of coronary artery disease in both black and white men. However, most studies showing associations between small apo(a) and CHD events did not adjust for total Lp(a) levels, 32 and smaller apo(a) isoforms are associated with higher total Lp(a) levels. 33 In addition, a recent analysis showed that although total Lp(a) levels were associated with CHD events after adjustment for apo(a) isoform size, the reverse was not true. 34 Similarly, lower LDL-C and higher HDL-C levels in blacks might protect against risk conferred by elevated Lp(a) levels [35] [36] [37] because treatment of elevated LDL-C in individuals with elevated Lp(a) has been shown to attenuate the increased risk for CHD events. 38 Our analyses extend the previously observed associations between small apo(a) isoforms and CVD events to show that total Lp(a) levels were also associated with incident CVD events in blacks. Prior studies included few black participants and consequently few CVD events, leading to limited statistical power. The sizable number of black participants and careful ascertainment of CVD events over multiple visits in ARIC provided us with greater statistical power to evaluate associations between Lp(a) levels and CVD events in blacks. Our analyses showed that elevated Lp(a) levels were associated with both CHD events and ischemic strokes in blacks, and the magnitude of risk associated with each race-specific 1-SD increment in log Lp(a) level was comparable to that in whites. The higher risk estimates for ischemic strokes than for incident CHD events in our study suggest that elevated Lp(a) in blacks might confer higher risk for a cerebrovascular event than for a coronary vascular event, which may also contribute to the lack of association in smaller studies that assessed only CHD as the outcome. 5, 13, 14 Our findings of increased CVD risk in individuals with Lp(a) levels Ͼ30 mg/dL are broadly consistent with the recommendation of a consensus statement from the European Atherosclerosis Society. 18 This consensus statement recommends desirable Lp(a) levels to be Ͻ80th percentile (ϽϷ50 mg/dL), and our findings (Table 6 ) support these cutoffs (30 mg/dL by the original ARIC visit-1 assay is roughly equivalent to 39 mg/dL by the newer isoform size-insensitive assay).
To our knowledge, this is the largest epidemiological study to date evaluating the associations between Lp(a) and CVD events in blacks. Our study has limitations. The Lp(a) mass assay used in the ARIC study measured the total protein mass and could be affected by variations in apo(a) size secondary to variable numbers of kringle 4 type 2 repeats. The number of kringle 4 type 2 repeats can vary from 3 to 40 per apo(a) particle, is genetically determined, and affects the measurement obtained with the assay. 33 A newer molar assay developed by Marcovina et al, 31, 39, 40 which is directed toward kringle 4 type 9 and is not affected by the number of kringle 4 type 2 repeats, is available but was not originally used in the ARIC study. However, our analyses showed good correlation between the original Lp(a) assay used on ARIC visit-1 samples and a newer assay insensitive to apo(a) isoform size. It is also interesting to note that in the meta-analysis conducted by the Emerging Risk Factors Collaboration, 1 relative risk for CHD was increased regardless of the apo(a) isoform sensitivity of the assay. Apo(a) isoform information is not available for the ARIC cohort; small apo(a) isoforms, in addition to being associated with higher plasma Lp(a) levels, 33 may be more atherogenic than large apo(a) isoforms. 41 Another limitation is that we examined only associations and did not perform tests for discrimination, calibration, and reclassification.
In conclusion, elevated Lp(a) levels were associated with incident CVD events in blacks in the ARIC study, and this risk was comparable to that in whites. Elevated Lp(a) levels should therefore be considered a risk factor for CVD in blacks. 
